1-4 of 4
Tom Van De Berg
Close
Sort by
Journal Articles

One Thrombin Generation Method Can Monitor Both Standard and Extended Half Life FVIII Products in Haemophilia a Patients with or without Emicizumab

Floor C.J.I. Moenen, Tom van de Berg, Arian van der Veer, Rene Van Oerle, Dave Hellenbrand, Henri M.H. Spronk, Erik A.M. Beckers, Yvonne M.C. Henskens
Journal: Blood
Blood (2022) 140 (Supplement 1): 11292–11293.
https://doi.org/10.1182/blood-2022-167297
Published: 2022
Journal Articles

Optimization of Thrombin Generation in Hemophilia a

Tom Van De Berg, Erik AM Beckers, Tilman M. Hackeng
Journal: Blood
Blood (2021) 138 (Supplement 1): 4232.
https://doi.org/10.1182/blood-2021-147165
Published: 2021
Journal Articles

A Novel Quali-Quantitative Defect of VWF

Tom Van De Berg, Alice Todaro, Joyce van Beers, Kanin Wichapong, Floor Heubel-Moenen, Elisabetta Castoldi, Yvonne M.C. Henskens, Erik AM Beckers
Journal: Blood
Blood (2021) 138 (Supplement 1): 1032.
https://doi.org/10.1182/blood-2021-147899
Published: 2021
Journal Articles

Novel Thermostable Inhibitor of Contact Activation Tica Effectively Blocks Contact Activation in Low Tissue Factor Thrombin Generation

Tom Van De Berg, MD, Dennis P.L. Suylen, M.G.L. Christella D. Thomassen, Rene van Oerle, Henri M.H. Spronk, PhD, Rafael Apitz, PhD, H. Coenraad Hemker, MD PhD, Tilman M. Hackeng, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1146.
https://doi.org/10.1182/blood-2019-130875
Published: 2019